STRATA Skin Sciences Inc (NASDAQ:SSKN) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $5.67 for the company and are expecting that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also assigned STRATA Skin Sciences an industry rank of 103 out of 256 based on the ratings given to its competitors.
Several research analysts recently issued reports on SSKN shares. Zacks Investment Research cut STRATA Skin Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, June 1st. Northland Securities reissued a “buy” rating and issued a $7.00 price objective on shares of STRATA Skin Sciences in a research note on Tuesday, May 14th. ValuEngine cut STRATA Skin Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, HC Wainwright set a $5.00 price objective on STRATA Skin Sciences and gave the stock a “buy” rating in a research note on Monday, July 8th.
NASDAQ:SSKN traded up $0.02 during midday trading on Monday, hitting $2.87. The stock had a trading volume of 23,600 shares, compared to its average volume of 59,895. STRATA Skin Sciences has a one year low of $1.86 and a one year high of $3.88. The company’s 50-day simple moving average is $2.59.
Institutional investors have recently made changes to their positions in the stock. Meitav Dash Investments Ltd. grew its position in STRATA Skin Sciences by 12.8% in the first quarter. Meitav Dash Investments Ltd. now owns 807,234 shares of the medical device company’s stock worth $2,314,000 after acquiring an additional 91,418 shares in the last quarter. Renaissance Technologies LLC grew its position in STRATA Skin Sciences by 6.7% in the second quarter. Renaissance Technologies LLC now owns 1,100,116 shares of the medical device company’s stock worth $2,739,000 after acquiring an additional 69,300 shares in the last quarter. Creative Planning grew its position in STRATA Skin Sciences by 42.9% in the second quarter. Creative Planning now owns 50,000 shares of the medical device company’s stock worth $125,000 after acquiring an additional 15,000 shares in the last quarter. Northern Trust Corp bought a new stake in STRATA Skin Sciences in the fourth quarter worth approximately $36,000. Finally, Acadian Asset Management LLC grew its position in STRATA Skin Sciences by 35.2% in the second quarter. Acadian Asset Management LLC now owns 52,715 shares of the medical device company’s stock worth $131,000 after acquiring an additional 13,716 shares in the last quarter. Hedge funds and other institutional investors own 30.98% of the company’s stock.
STRATA Skin Sciences Company Profile
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
See Also: Call Option
Get a free copy of the Zacks research report on STRATA Skin Sciences (SSKN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.